Pfizer Inc. (NYSE: PFE) presented results from multiple phase 2b studies of berobenatide, an investigational monthly GLP-1 receptor agonist for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE